Clinical Trials Browser

ALK-positive Advanced NSCLC × brigatinib × Clear all

NCT03535740 2025-07-31

ALTA-2

Phase 2 Completed

103 enrolled 23 charts

ALK-positive Advanced NSCLC

NCT03410108 2024-05-08

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

104 enrolled 22 charts

ALK-positive Advanced NSCLC